Overview

Product & Indication Development Stage
Preclinical Phase 1 Phase 2 Phase 3 Market
Meloxicam
IV Formulation Acute post operative pain
Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase complete
Phase 3 Phase in progress
Market Phase not started
IM Formulation Acute pain
Preclinical Phase complete
Phase 1 Phase in progress
Phase 2 Phase not started
Phase 3 Phase not started
Market Phase not started
Dexmedetomidine (“Dex”)
Dex-IN (intranasal) Peri-procedural pain
Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase in progress
Phase 3 Phase not started
Market Phase not started
Dex-IN (intranasal) Cancer breakthrough pain
Preclinical Phase complete
Phase 1 Phase in progress
Phase 2 Phase not started
Phase 3 Phase not started
Market Phase not started
Dex-SL (sublingual)
Preclinical Phase complete
Phase 1 Phase in progress
Phase 2 Phase not started
Phase 3 Phase not started
Market Phase not started
Fadolmidine (“Fado”)
Intrathecal
Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase in progress
Phase 3 Phase not started
Market Phase not started
Topical
Preclinical Phase complete
Phase 1 Phase in progress
Phase 2 Phase not started
Phase 3 Phase not started
Market Phase not started

This information reflects public disclosures current as of April , 2016

Recro's product pipeline will change over time as the products move through the drug development process. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Recro's most recent Form 10-K and in Recro's periodic reports on Form 10-Q and Form 8-K, and actual results may vary materially. Recro is providing this information as of the date above and does not undertake any obligation to update any forward-looking statements contained in this table as a result of new information, future events or otherwise.